MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis
USA - NASDAQ:MYGN - US62855J1043 - Common Stock
8.15 USD
+0.1 (+1.24%)
8.3 USD
+0.15 (+1.84%)
Taking everything into account, MYGN scores 3 out of 10 in our fundamental rating. MYGN was compared to 534 industry peers in the Biotechnology industry. The financial health of MYGN is average, but there are quite some concerns on its profitability. MYGN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
MYGN had positive earnings in the past year.
In the past year MYGN has reported a negative cash flow from operations.
In the past 5 years MYGN always reported negative net income.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
With a Return On Assets value of -58.36%, MYGN perfoms like the industry average, outperforming 44.57% of the companies in the same industry.
MYGN has a Return On Equity (-101.83%) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.36% | ||
| ROE | -101.83% | ||
| ROIC | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 70.44%, MYGN belongs to the top of the industry, outperforming 81.65% of the companies in the same industry.
MYGN's Gross Margin has declined in the last couple of years.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
2. Health
2.1 Basic Checks
MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
The number of shares outstanding for MYGN has been increased compared to 5 years ago.
MYGN has a worse debt/assets ratio than last year.
2.2 Solvency
MYGN has an Altman-Z score of 0.33. This is a bad value and indicates that MYGN is not financially healthy and even has some risk of bankruptcy.
MYGN has a Altman-Z score of 0.33. This is comparable to the rest of the industry: MYGN outperforms 59.55% of its industry peers.
MYGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.33 |
ROIC/WACCN/A
WACC9.3%
2.3 Liquidity
MYGN has a Current Ratio of 1.42. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
MYGN has a Current ratio of 1.42. This is amonst the worse of the industry: MYGN underperforms 82.02% of its industry peers.
MYGN has a Quick Ratio of 1.27. This is a normal value and indicates that MYGN is financially healthy and should not expect problems in meeting its short term obligations.
MYGN's Quick ratio of 1.27 is on the low side compared to the rest of the industry. MYGN is outperformed by 83.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.27 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 120.00% over the past year.
The Earnings Per Share has been growing by 86.63% on average over the past years. This is a very strong growth
Looking at the last year, MYGN shows a small growth in Revenue. The Revenue has grown by 3.83% in the last year.
Measured over the past years, MYGN shows a decrease in Revenue. The Revenue has been decreasing by -0.32% on average per year.
EPS 1Y (TTM)120%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)3.83%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%0.76%
3.2 Future
MYGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.77% yearly.
Based on estimates for the next years, MYGN will show a small growth in Revenue. The Revenue will grow by 3.25% on average per year.
EPS Next Y-96.38%
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
EPS Next 5Y15.77%
Revenue Next Year-2.05%
Revenue Next 2Y1.74%
Revenue Next 3Y3.07%
Revenue Next 5Y3.25%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 74.09, the valuation of MYGN can be described as expensive.
91.39% of the companies in the same industry are more expensive than MYGN, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 26.89, MYGN is valued quite expensively.
The Price/Forward Earnings ratio is 77.64, which means the current valuation is very expensive for MYGN.
Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 88.02% of the companies in the same industry.
MYGN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.99.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 74.09 | ||
| Fwd PE | 77.64 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MYGN's earnings are expected to grow with 18.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
5. Dividend
5.1 Amount
MYGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.15
+0.1 (+1.24%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.36%
Inst Owner Change1.33%
Ins Owners2.62%
Ins Owner Change11.19%
Market Cap758.28M
Revenue(TTM)832.90M
Net Income(TTM)-395100000
Analysts53.68
Price Target7.31 (-10.31%)
Short Float %8.66%
Short Ratio6.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)338.77%
Min EPS beat(2)49.87%
Max EPS beat(2)627.66%
EPS beat(4)3
Avg EPS beat(4)219.97%
Min EPS beat(4)-2.9%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)217.89%
EPS beat(12)9
Avg EPS beat(12)130.16%
EPS beat(16)13
Avg EPS beat(16)120.51%
Revenue beat(2)1
Avg Revenue beat(2)-0.38%
Min Revenue beat(2)-4.24%
Max Revenue beat(2)3.49%
Revenue beat(4)1
Avg Revenue beat(4)-0.99%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)4
Avg Revenue beat(8)0.45%
Revenue beat(12)6
Avg Revenue beat(12)-0.31%
Revenue beat(16)8
Avg Revenue beat(16)-0.11%
PT rev (1m)0%
PT rev (3m)-3.95%
EPS NQ rev (1m)-14.93%
EPS NQ rev (3m)-199.87%
EPS NY rev (1m)-24.88%
EPS NY rev (3m)146.2%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)0.48%
Revenue NY rev (1m)-0.11%
Revenue NY rev (3m)1.39%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 74.09 | ||
| Fwd PE | 77.64 | ||
| P/S | 0.91 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.95 | ||
| P/tB | 4.57 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.11
EY1.35%
EPS(NY)0.1
Fwd EY1.29%
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.22
OCFYN/A
SpS8.95
BVpS4.17
TBVpS1.78
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -58.36% | ||
| ROE | -101.83% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.44% | ||
| FCFM | N/A |
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 45.83% | ||
| Cap/Sales | 3.23% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.42 | ||
| Quick Ratio | 1.27 | ||
| Altman-Z | 0.33 |
F-Score5
WACC9.3%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)120%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-96.38%
EPS Next 2Y-10.14%
EPS Next 3Y18.28%
EPS Next 5Y15.77%
Revenue 1Y (TTM)3.83%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%0.76%
Revenue Next Year-2.05%
Revenue Next 2Y1.74%
Revenue Next 3Y3.07%
Revenue Next 5Y3.25%
EBIT growth 1Y25.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.33%
EBIT Next 3Y42.66%
EBIT Next 5Y15.6%
FCF growth 1Y60.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.39%
OCF growth 3YN/A
OCF growth 5YN/A
MYRIAD GENETICS INC / MYGN FAQ
What is the ChartMill fundamental rating of MYRIAD GENETICS INC (MYGN) stock?
ChartMill assigns a fundamental rating of 3 / 10 to MYGN.
Can you provide the valuation status for MYRIAD GENETICS INC?
ChartMill assigns a valuation rating of 2 / 10 to MYRIAD GENETICS INC (MYGN). This can be considered as Overvalued.
Can you provide the profitability details for MYRIAD GENETICS INC?
MYRIAD GENETICS INC (MYGN) has a profitability rating of 2 / 10.
How financially healthy is MYRIAD GENETICS INC?
The financial health rating of MYRIAD GENETICS INC (MYGN) is 4 / 10.